Benign Prostatic Hyperplasia (BPH) Clinical Trial
— ATHLETEOfficial title:
Aquablation vs. Holmium Laser Enucleation of the Prostate in the Treatment of Benign Prostatic Hyperplasia in Medium to Large Size Prostates: A Prospective Randomized Trial
Verified date | January 2021 |
Source | Cantonal Hospital of St. Gallen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Benign prostatic hyperplasia (BPH) is one of the most common diseases in men. As BPH progresses, surgical treatments often become necessary. Holmium enucleation of the prostate (HoLEP) is an established procedure in the surgical treatment of BPH, especially for medium to large prostates. The long learning curve, the length of surgery, and expensive equipment still limit the availability of HoLEP to a few specialized centers. Recently, a new method for treating BPH called aquablation has become commercially available. This technique uses real-time ultrasound imaging in combination with a robotic high-pressure water jet programmed and guided by the surgeon to resect prostate tissue. A RCT has shown functional results similar to transurethral resection of the prostate (TURP) for small to medium size prostates . However, so far there are no controlled studies assessing whether Aquablation provides patient reported and functional outcomes that are non-inferior compared to HoLEP in medium size to large prostates (the latter cannot be operated by TURP due to its size limitations). As aquablation offers some obvious advantages compared to HoLEP regarding learning curve and operation time, the aim of this study is to test whether efficacy and safety of aquablation are non- inferior compared to HoLEP in patients with medium to large size prostates, which would clearly support the use of aquablation and change everyday clinical practice.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | November 2027 |
Est. primary completion date | April 2023 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 45 Years and older |
Eligibility | Inclusion Criteria: - Men =45 years of age - Patient must be a candidate for HoLEP - Refractory to medical therapy or patient is not willing to consider (further) medical treatment - Patient has a prostate size of at least 50 ml and not more than 150ml, measured by transrectal ultrasound (TRUS) - IPSS =12 - QoL=3 - Qmax = 15 ml/s with a minimum voided volume = 125 ml or patient in urinary retention - Written informed consent Exclusion Criteria: - Neurogenic lower urinary tract dysfunction - Urethral stenosis - Preinterventionally proven adenocarcinoma of the prostate - Nickel allergy - Not able to complete questionnaires due to cognitive or thought disorders - Language skills insufficient for informed consent and / or completion of questionnaires |
Country | Name | City | State |
---|---|---|---|
Switzerland | Cantonal Hospital St. Gallen | Saint Gallen |
Lead Sponsor | Collaborator |
---|---|
Dr. med. Gautier Müllhaupt |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | International Prostate Symptoms Score (IPSS) | The International Prostate Symptom Score (IPSS) can be utilized to measure the severity of lower urinary tract symptoms. The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03052049 -
Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
|
N/A | |
Recruiting |
NCT04757116 -
A Randomized, International Study to Assess the Safety of iTind Compared to UroLift
|
N/A | |
Completed |
NCT03460873 -
Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate
|
||
Completed |
NCT01218243 -
An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
|
Phase 2 | |
Completed |
NCT01566292 -
Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT00407953 -
PROLIEVE® Post-Marketing Study TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)
|
Phase 4 | |
Completed |
NCT03191734 -
French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
|
N/A | |
Recruiting |
NCT04838769 -
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
|
N/A | |
Completed |
NCT03856242 -
Benign Prostatic Hyperplasia and Ischemic Heart DIsease
|
Phase 4 | |
Completed |
NCT04032067 -
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Completed |
NCT02505919 -
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
|
N/A | |
Completed |
NCT02855892 -
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
|
Phase 2 | |
Completed |
NCT02145208 -
Study to Assess the Efficacy of Medi-Tate iTind Device
|
N/A | |
Completed |
NCT00970632 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
|
Phase 3 | |
Recruiting |
NCT02592473 -
Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT00945490 -
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
|
Phase 3 | |
Completed |
NCT00759135 -
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
|
Phase 2 | |
Completed |
NCT00224107 -
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
|
Phase 3 | |
Recruiting |
NCT04648176 -
Application of MOSES Technology in BPH
|
N/A | |
Terminated |
NCT00651807 -
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
|
Phase 2 |